BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/22/2014 5:28:00 PM | Browse: 501 | Download: 496
Publication Name World Journal of Clinical Oncology
Manuscript ID 8543
Country of Manuscript Source United States
Received
2013-12-30 10:38
Peer-Review Started
2013-12-30 11:13
To Make the First Decision
2014-02-27 10:49
Return for Revision
2014-03-04 20:58
Revised
2014-03-22 00:04
Second Decision
2014-06-20 11:54
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2014-06-20 12:06
Articles in Press
2014-06-20 13:19
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2014-07-24 14:16
Publish the Manuscript Online
2014-08-01 16:16
ISSN 2218-4333 (online)
Open Access
Copyright
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Specialty Oncology
Manuscript Type Topic Highlights
Article Title Management of tyrosine kinase inhibitor resistance in lung cancer with EGFR mutation
Manuscript Source Invited Manuscript
All Author List Kevin Becker and Yiqing Xu
Funding Agency and Grant Number
Corresponding author Kevin Becker, MD, Division of Hematology and Oncology, Maimonides Cancer Center, 6300 Eighth Ave, Brooklyn, NY 11201, United States. kbecker@maimonidesmed.org
Keywords Epidermal growth factor receptor mutation; Tyrosine kinase inhibitor; Lung cancer; Adenocarcinoma; Resistance; Targeted therapy
Core Tip The causes of epidermal growth factor receptor tyrosine kinase inhibitor (TKI) treatment failure including pharmacokinetic failure, intrinsic resistance and acquired resistance are discussed. We review the molecular mechanisms of resistance and the options for clinical management of disease progression. Promising investigational strategies for overcoming TKI resistance are highlighted.
Publish Date 2014-08-01 16:16
Citation Becker K, Xu Y. Management of tyrosine kinase inhibitor resistance in lung cancer with EGFR mutation. World J Clin Oncol 2014; 5(4): 560-567
Url http://www.wjgnet.com/2218-4333/full/v5/i4/560.htm
DOI http://dx.doi.org/10.5306/wjco.v5.i4.560
Full Article (PDF) WJCO-5-560.pdf
Full Article (Word) WJCO-5-560.doc
Manuscript File 8543-Review.docx
Answering Reviewers 8543-Answering reviewers.pdf
Copyright License Agreement 8543-Copyright assignment.pdf
Peer-review Report 8543-Peer review(s).pdf
Scientific Misconduct Check 8543-CrossCheck.jpg
Scientific Editor Work List 8543-Scientific editor work list.pdf